vs
Side-by-side financial comparison of Borealis Foods Inc. (BRLS) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $7.1M, roughly 1.3× Borealis Foods Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -53.2%, a 53.8% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -12.0%). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -2.4%).
Borealis Foods Inc is a food technology enterprise specializing in developing and producing high-quality plant-based protein products including plant-based meat alternatives. It mainly serves retail and food service customers across North America and Europe, focusing on delivering affordable, nutritious sustainable food options matching the taste of conventional animal-derived meat.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
BRLS vs SSKN — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.1M | $9.3M |
| Net Profit | $-3.8M | $58.0K |
| Gross Margin | 14.6% | 61.8% |
| Operating Margin | -27.1% | 5.3% |
| Net Margin | -53.2% | 0.6% |
| Revenue YoY | -12.0% | -3.0% |
| Net Profit YoY | 21.8% | 101.3% |
| EPS (diluted) | $-0.18 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $9.3M | ||
| Q3 25 | $7.1M | $6.9M | ||
| Q2 25 | $7.2M | $7.7M | ||
| Q1 25 | $6.8M | $6.8M | ||
| Q4 24 | $6.8M | $9.6M | ||
| Q3 24 | $8.1M | $8.8M | ||
| Q2 24 | $5.5M | $8.4M | ||
| Q1 24 | $7.9M | $6.8M |
| Q4 25 | — | $58.0K | ||
| Q3 25 | $-3.8M | $-1.6M | ||
| Q2 25 | $-4.6M | $-2.6M | ||
| Q1 25 | $-4.2M | $-2.1M | ||
| Q4 24 | $-5.8M | $-4.6M | ||
| Q3 24 | $-4.8M | $-2.1M | ||
| Q2 24 | $-6.3M | $-91.0K | ||
| Q1 24 | $-8.4M | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | 14.6% | 60.4% | ||
| Q2 25 | 7.2% | 56.2% | ||
| Q1 25 | 13.1% | 53.5% | ||
| Q4 24 | 3.7% | 61.4% | ||
| Q3 24 | 15.8% | 60.1% | ||
| Q2 24 | 7.7% | 59.0% | ||
| Q1 24 | 3.1% | 45.6% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | -27.1% | -16.9% | ||
| Q2 25 | -46.7% | -30.1% | ||
| Q1 25 | -42.6% | -25.0% | ||
| Q4 24 | -68.4% | -44.7% | ||
| Q3 24 | -44.8% | -18.2% | ||
| Q2 24 | -94.8% | -5.7% | ||
| Q1 24 | -88.3% | -42.7% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | -53.2% | -23.4% | ||
| Q2 25 | -64.0% | -33.6% | ||
| Q1 25 | -61.2% | -31.2% | ||
| Q4 24 | -85.3% | -47.6% | ||
| Q3 24 | -59.8% | -23.6% | ||
| Q2 24 | -115.0% | -1.1% | ||
| Q1 24 | -106.8% | -49.8% |
| Q4 25 | — | $0.14 | ||
| Q3 25 | $-0.18 | $-0.36 | ||
| Q2 25 | $0.21 | $-0.62 | ||
| Q1 25 | $-0.20 | $-0.51 | ||
| Q4 24 | $-0.82 | $-2.01 | ||
| Q3 24 | $-0.23 | $-0.51 | ||
| Q2 24 | $0.29 | $-0.03 | ||
| Q1 24 | $-0.49 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $-12.9M | $2.9M |
| Total Assets | $56.3M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.9M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | — | $6.5M | ||
| Q4 24 | — | $7.3M | ||
| Q3 24 | — | $7.1M | ||
| Q2 24 | — | $5.5M | ||
| Q1 24 | — | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | — | $2.9M | ||
| Q3 25 | $-12.9M | $1.3M | ||
| Q2 25 | $-9.2M | $532.0K | ||
| Q1 25 | $-4.8M | $3.0M | ||
| Q4 24 | $-695.9K | $5.0M | ||
| Q3 24 | $5.1M | $9.4M | ||
| Q2 24 | $9.9M | $9.5M | ||
| Q1 24 | $16.2M | $9.4M |
| Q4 25 | — | $30.5M | ||
| Q3 25 | $56.3M | $30.7M | ||
| Q2 25 | $57.3M | $29.5M | ||
| Q1 25 | $58.4M | $33.0M | ||
| Q4 24 | $60.0M | $34.9M | ||
| Q3 24 | $61.9M | $39.4M | ||
| Q2 24 | $63.6M | $38.8M | ||
| Q1 24 | $70.3M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-190.6K | $-239.0K |
| Free Cash FlowOCF − Capex | — | $-551.0K |
| FCF MarginFCF / Revenue | — | -5.9% |
| Capex IntensityCapex / Revenue | — | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-239.0K | ||
| Q3 25 | $-190.6K | $-64.0K | ||
| Q2 25 | $-2.2M | $-1.9M | ||
| Q1 25 | $-1.4M | $-550.0K | ||
| Q4 24 | $-819.4K | $703.0K | ||
| Q3 24 | $-3.3M | $-302.0K | ||
| Q2 24 | $-4.2M | $591.0K | ||
| Q1 24 | $-6.8M | $-804.0K |
| Q4 25 | — | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | $-1.4M | $-749.0K | ||
| Q4 24 | $-951.6K | $199.0K | ||
| Q3 24 | $-3.7M | $-364.0K | ||
| Q2 24 | $-4.7M | $246.0K | ||
| Q1 24 | $-7.3M | $-1.5M |
| Q4 25 | — | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | — | -26.1% | ||
| Q1 25 | -20.3% | -11.0% | ||
| Q4 24 | -14.1% | 2.1% | ||
| Q3 24 | -46.1% | -4.1% | ||
| Q2 24 | -86.7% | 2.9% | ||
| Q1 24 | -92.7% | -22.6% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | 0.2% | 2.9% | ||
| Q4 24 | 2.0% | 5.3% | ||
| Q3 24 | 5.6% | 0.7% | ||
| Q2 24 | 9.4% | 4.1% | ||
| Q1 24 | 7.0% | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BRLS
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
